Antitumor Activity of Desmopressin (dDAVP) and the New Analog [V4Q5]dDAVP in Human Small Cell Lung Cancer


Introduction: Lung cancer is the main cause of cancer death. Non small cell lung cancer (NSCLC) cause about 85% of cases and small cell lung cancer (SCLC) represents 15%. Therapy resistance is commonly related with a transformation from adenocarcinoma to SCLC. SCLC shows neuroendocrine (NE) features and exhibits aggressive behavior. In vitro production of vasopressin (AVP) was reported in SCLC. The AVP V1 receptors are associated with mitogenic signaling pathways, while AVP V2 receptor (V2r) is related with an opposite effect. DDAVP is a synthetic analog of AVP that acts as a selective agonist for V2r. DDAVP displays cytostatic and antimetastatic properties in breast and colorectal cancer. In our laboratory a new analog, [V4Q5]dDAVP, showed improved cytostatic activity

Aim(s): In this study we evaluated the antitumor ability of the analogs mediated by V2r on a human SCLC cell line.

Materials and methods: We used NCI-H82. V2r expression and NE markers were confirmed by immunofluorescence and qRT-PCR. Cytostatic activity of the analogs was studied with MTS assay. V2r was depleted using siRNA. The tumor progression was evaluated with a mouse xenograft model.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Pifano M, Garona J, Alonso D, Ripoll G,

Keywords: v2r, antitumor, NE,

To read the full abstract, please log into your ENETS Member account.